ChiCTR2600118110 版本V1.0 版本创建时间2026/02/02 14:51:15 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600118110 

最近更新日期:

Date of Last Refreshed on:

2026-02-02 14:51:09 

注册时间:

Date of Registration:

2026-02-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

"雾镜成像+点阵离焦技术”视力管理镜片在青少年儿童近视防控中的应用

Public title:

Application of "Fog Mirror Imaging +Dot Matrix Defocus Technology" Vision Management Lenses in Myopia Control for Adolescents and Children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

"雾镜成像=点阵离焦技术”视力管理镜片在青少年儿童近视防控中的应用

Scientific title:

Application of "Fog Mirror Imaging = Dot Matrix Defocus Technology" Vision Management Lenses in Myopia Control for Adolescents and Children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李影 

研究负责人:

李影 

Applicant:

Li Ying  

Study leader:

Li Ying 

申请注册联系人电话:

Applicant telephone:

+86 151 6213 0727

研究负责人电话:

Study leader's
telephone:

+86 151 6213 0727

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liying20220318@163.com

研究负责人电子邮件:

Study leader's E-mail:

liying20220318@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省徐州市泉山区中山北路19号

研究负责人通讯地址:

江苏省徐州市泉山区中山北路19号

Applicant address:

No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province

Study leader's address:

No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

221002

研究负责人邮政编码:

Study leader's postcode:

221002

申请人所在单位:

徐州医科大学附属徐州市立医院

Applicant's institution:

Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University

研究负责人所在单位:

徐州医科大学附属徐州市立医院

Affiliation of the Leader:

Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

xyyll(2005)-XJSFX-275

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

徐州市第一人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First People's Hospital of Xuzhou

伦理委员会批准日期:

Date of approved by ethic committee:

2025-10-20 00:00:00

伦理委员会联系人:

张颖

Contact Name of the ethic committee:

Zhang Ying

伦理委员会联系地址:

江苏省徐州市泉山区中山北路19号

Contact Address of the ethic committee:

No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 516 6816 7579

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

徐州市第一人民医院

Primary sponsor:

The First People's Hospital of Xuzhou

研究实施负责(组长)单位地址:

江苏省徐州市泉山区中山北路19号

Primary sponsor's address:

No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

徐州市第一人民医院

具体地址:

江苏省徐州市泉山区中山北路19号

Institution
hospital:

The First People's Hospital of Xuzhou

Address:

No. 19, North Zhongshan Road, Quanshan District, Xuzhou City, Jiangsu Province

经费或物资来源:

上海京鸿光学有限公司

Source(s) of funding:

Shanghai Jinghong Optics Co., Ltd.

研究疾病:

近视  

Target disease:

myopia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在通过一项随机、对照、非劣效性临床试验,评估双控镜片对比新乐学(DIMS)镜片在延缓青少年近视进展方面的有效性和安全性。主要目的是验证配戴双控镜片12个月后,在控制眼轴增长方面是否非劣于DIMS镜片。  

Objectives of Study:

This study aimed to evaluate the efficacy and safety of dual-control lenses in slowing the progression of myopia in adolescents by conducting a randomized, controlled, non-inferiority clinical trial, in comparison with Defocus Incorporated Multiple Segments (DIMS) lenses. The primary objective was to verify whether dual-control lenses are non-inferior to DIMS lenses in controlling axial length elongation after 12 months of wear.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄6至12岁,性别不限; 2.屈光状态符合下述条件: (1)睫状肌麻痹后电脑验光检测双眼等效球光度在 -0.50D~-6.00D之间(包括-0.50D和-6.00D); (2)睫状肌麻痹后电脑验光检测双眼散光均不超过2.0D; (3)睫状肌麻痹后电脑验光检测双眼屈光参差小于2.00D; 3.双眼眼内压正常(大于等于10mmHg,小于等于21mmHg); 4.任一眼最佳矫正远视力优于或等于0.8; 5.双眼无弱视或其他任何眼球病理性改变; 6.患者本人清楚了解,自愿参加该项研究,并由本人及家长/监护人签署知情同意书。

Inclusion criteria

1. Age 6 to 12 years, any gender; 2. Refractive status meets the following conditions: (1) After cycloplegia, computer-based refraction shows both eyes with an equivalent spherical diopter between -0.50D and -6.00D (including -0.50D and -6.00D); (2) After cycloplegia, computer-based refraction shows astigmatism in both eyes not exceeding 2.0D; (3) After cycloplegia, computer-based refraction shows anisometropia in both eyes less than 2.00D; 3. Intraocular pressure in both eyes is normal (greater than or equal to 10 mmHg, less than or equal to 21 mmHg); 4. Best-corrected distance visual acuity in either eye is equal to or better than 0.8; 5. No amblyopia or any other pathological changes in either eye; 6. The patient fully understands and voluntarily participates in this study, and the informed consent form is signed by both the patient and the parent/guardian.

排除标准:

1.有任何可能与近视发展相关或影响眼屈光状态的眼部或全身疾病(如先天性白内障,早产儿视网膜病变,马凡氏综合征,糖尿病等)或疾病; 2.存在显性斜视或明显双眼视功能异常; 3.不愿配合访视者; 4.研究者判断患者不适合入选的其它情况; 5.正在参加其它可能对本研究有影响的临床试验,或者三个月内使用过其他近视防控手段,如低浓度阿托品或者角膜塑形镜,红光治疗等。

Exclusion criteria:

1. Any ocular or systemic diseases that may be related to the development of myopia or affect refractive status (such as congenital cataract, retinopathy of prematurity, Marfan syndrome, diabetes, etc.); 2. Presence of manifest strabismus or obvious binocular visual function abnormalities; 3. Unwillingness to cooperate with visits; 4. Other situations where the researcher determines the patient is not suitable for inclusion; 5. Currently participating in other clinical trials that may affect this study, or having used other myopia control methods within the past three months, such as low-concentration atropine, orthokeratology lenses, red light therapy, etc.

研究实施时间:

Study execute time:

From 2026-02-04 00:00:00 To 2027-05-07 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-04 00:00:00 To 2027-05-07 00:00:00

干预措施:

Interventions:

组别:

双控镜片组

样本量:

60

Group:

Dual-control Lens Group

Sample size:

干预措施:

配戴双控镜片

干预措施代码:

Intervention:

Wearing bi-focal lenses

Intervention code:

组别:

新乐学(DIMS)镜片组

样本量:

60

Group:

Xinle Learning (DIMS) Lens group

Sample size:

干预措施:

配戴新乐学(DIMS)镜片

干预措施代码:

Intervention:

Wearing New LuxVision (DIMS) lenses

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

徐州市第一人民医院 

单位级别:

三甲 

Institution
hospital:

Xuzhou First People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

眼轴

指标类型:

主要指标

Outcome:

Axial length

Type:

Primary indicator

测量时间点:

基线,3个月,6个月,12个月

测量方法:

Measure time point of outcome:

Baseline ,3 month ,6 month ,12 month

Measure method:

指标中文名:

等效球镜

指标类型:

主要指标

Outcome:

Spherical Equivalent, SE

Type:

Primary indicator

测量时间点:

基线,3个月,6个月,12个月

测量方法:

Measure time point of outcome:

Baseline ,3 month ,6 month ,12 month

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 6 years
最大 Max age 12 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由东南大学公共卫生学院阮增良副教授用R软件产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Associate Professor Zengliang Ruan, from the School of Public Health, Southeast University, was responsible for generating the random sequence with R software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对受试者,检查人员,医生设盲

Blinding:

Blinding for subjects, examiners, and doctors

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-02 14:51:09